Sekiguchi, Naohiro
Kasahara, Senji
Miyamoto, Toshihiro
Kiguchi, Toru
Ohno, Hitoshi
Takagi, Taiga
Tachibana, Masaya
Sumi, Hiroyuki
Kakurai, Yasuyuki
Yamashita, Tomonari
Usuki, Kensuke http://orcid.org/0000-0002-1216-4470
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd
Article History
Received: 27 May 2022
Revised: 30 September 2022
Accepted: 30 September 2022
First Online: 19 October 2022
Declarations
:
: Naohiro Sekiguchi received research funds from Ono, A2 Healthcare, Astellas, Janssen, MSD, Otsuka, Pfizer, PPD-SNBL, Sumimoto Dainippon, Daiichi Sankyo, and Bristol Myers Squibb. Senji Kasahara received research funds from Daiichi Sankyo. Toshihiro Miyamoto received research funds from Daiichi Sankyo and speaker fees from Bristol Myers Squibb, Otsuka, MSD, Astellas, Astellas Amgen, Celgene, AbbVie, and Takeda. Toru Kiguchi received speaker fees from Bristol Myers Squibb and Novartis, as well as research funds from Bristol Myers Squibb, Daiichi Sankyo, Otsuka, MSD, Takeda, Astella, Nippon Shinyaku, Novartis, Sumimoto Dainippon, Janssen, SymBio, Celgene, and Sanofi. Hitoshi Ohno received research funds from Daiichi Sankyo. Taiga Takagi, Masaya Tachibana, Hiroyuki Sumi, Yasuyuki Kakurai, and Tomonari Yamashita are employees of Daiichi Sankyo. Kensuke Usuki received speaker fees from Novartis as well as research funds from Astellas, Alexion, AbbVie, Gilead, SymBio, Daiichi Sankyo, Sumimoto Dainippon, Chugai, Otsuka, Novartis, Bristol Myers Squibb, Takeda, Astellas Amgen, Apellis, and Nippon Shinyaku.
: This study was conducted and complied with all international and local laws, the principles of the Declaration of Helsinki, and the Good Clinical Practice Guidelines. All patients provided written voluntary informed consent to participate in this study. The study protocol and all its amendments were approved by the relevant institutional review boards or independent ethics committees.